Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析

◆英語タイトル:Nanobiotix SA (NANO) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14866
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nanobiotix SA (Nanobiotix) is a late stage clinical company which develops nanomedicines for the treatment of cancers. The company develops first-in-class products utilizing its proprietary technology NanoXray, based on the physical mode of action of nanoparticles that increase the X-rays dose energy absorption within tumor cells, without increasing the dose to the surrounding healthy tissues. Its lead product candidate NBTXR3, a cancer immunotherapy nanoparticles activated with radiotherapy is develped to destroy tumors and metastasis through immunogenic cell death leading to activation of the immune system. The company works in collaboration with Providence Cancer Institute, Weill Cornell Medicine and PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. It has operations with offices in the US, Spain and Germany. The company is a spin-off from the State University of New York (SUNY). Nanobiotix is headquartered in Paris, France.

Nanobiotix SA Key Recent Developments

Jan 16,2019: Nanobiotix Plans to Conduct Registered public offering in the United States
Nov 15,2018: Nanobiotix revenues for the 3rd quarter of 2018
Oct 19,2018: NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
Sep 21,2018: Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20, 2018

This comprehensive SWOT profile of Nanobiotix SA provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Nanobiotix SA including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Nanobiotix SA – Key Information
Nanobiotix SA – Overview
Nanobiotix SA – Key Employees
Nanobiotix SA – Key Employee Biographies
Nanobiotix SA – Key Operational Heads
Nanobiotix SA – Major Products and Services
Nanobiotix SA – History
Nanobiotix SA – Company Statement
Nanobiotix SA – Locations And Subsidiaries
Nanobiotix SA – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Nanobiotix SA – Business Description
Nanobiotix SA – Corporate Strategy
Nanobiotix SA – SWOT Analysis
SWOT Analysis – Overview
Nanobiotix SA – Strengths
Nanobiotix SA – Weaknesses
Nanobiotix SA – Opportunities
Nanobiotix SA – Threats
Nanobiotix SA – Key Competitors

Section 3 – Company Financial Performance Charts

Nanobiotix SA – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Nanobiotix SA, Key Information
Nanobiotix SA, Key Ratios
Nanobiotix SA, Share Data
Nanobiotix SA, Major Products and Services
Nanobiotix SA, History
Nanobiotix SA, Key Employees
Nanobiotix SA, Key Employee Biographies
Nanobiotix SA, Key Operational Heads
Nanobiotix SA, Other Locations
Nanobiotix SA, Subsidiaries
Nanobiotix SA, Key Manufacturing facilities
Nanobiotix SA, Key Competitors
Nanobiotix SA, SWOT Analysis
Nanobiotix SA, Ratios based on current share price
Nanobiotix SA, Annual Ratios
Nanobiotix SA, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Nanobiotix SA, Performance Chart
Nanobiotix SA, Ratio Charts

★海外企業調査レポート[Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • San Miguel Corporation:企業のM&A・事業提携・投資動向
    San Miguel Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's San Miguel Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Mercer LLC:企業の戦略的SWOT分析
    Mercer LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Exillon Energy Plc (EXI):企業の財務・戦略的SWOT分析
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • EnWave Corp (ENW):企業の財務・戦略的SWOT分析
    EnWave Corp (ENW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Norwegian Hull Club:企業の戦略・SWOT・財務情報
    Norwegian Hull Club - Strategy, SWOT and Corporate Finance Report Summary Norwegian Hull Club - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Verastem Inc (VSTM):企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • ELITechGroup Inc:企業の製品パイプライン分析2018
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cystic fibrosis, hematology, microbiology and molecular diagnostics. Its clinical chemistry produ …
  • Abbott Vascular Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abbott Vascular Inc (Abbott Vascular), formerly Perclose, Inc., a subsidiary of Abbott Laboratories, is a medical device company that develops manufactures and markets cardiovascular devices. The company offers coronary intervention, peripheral intervention, and structural heart products. It …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務情報
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Royal Dutch Shell Plc (RDSA):企業の財務・戦略的SWOT分析
    Royal Dutch Shell Plc (RDSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • NCC Group plc:企業の戦略・SWOT・財務分析
    NCC Group plc - Strategy, SWOT and Corporate Finance Report Summary NCC Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Cheesecake Factory Incorporated:戦略・SWOT・企業財務分析
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Envestnet, Inc.:企業のM&A・事業提携・投資動向
    Envestnet, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Envestnet, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Cajun Industries, LLC:企業の戦略的SWOT分析
    Cajun Industries, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mission Pharmacal Company-製薬・医療分野:企業M&A・提携分析
    Summary Mission Pharmacal Company (Mission Pharmacal) is a pharmaceutical company, which develops, manufactures and markets prescription, over-the-counter, and dietary supplement products. It offers products for conditions related to women’s health, urology, pediatrics, and dermatology, among others …
  • University of Bristol-医療機器分野:企業M&A・提携分析
    Summary University of Bristol (UOB) is an educational service provider that offers undergraduate and postgraduate courses and research services. The university offers courses in arts, biomedical sciences, engineering, medical and veterinary sciences, dentistry, science, and social sciences and law. …
  • Italcementi S.p.A:企業の戦略的SWOT分析
    Italcementi S.p.A - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Kuwait Reinsurance Company K.S.C.C.:企業の戦略・SWOT・財務情報
    Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report Summary Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • aTyr Pharma Inc (LIFE):企業の財務・戦略的SWOT分析
    Summary ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company’s ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to th …
  • Bristol-Myers Squibb Co (BMY):医療機器:M&Aディール及び事業提携情報
    Summary Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virolo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆